These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2830688)

  • 1. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections.
    Kovarik J; Mayer G; Pohanka E; Schwarz M; Traindl O; Graf H; Smolen J
    Transplantation; 1988 Feb; 45(2):402-5. PubMed ID: 2830688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients.
    Hirsch MS; Schooley RT; Cosimi AB; Russell PS; Delmonico FL; Tolkoff-Rubin NE; Herrin JT; Cantell K; Farrell ML; Rota TR; Rubin RH
    N Engl J Med; 1983 Jun; 308(25):1489-93. PubMed ID: 6304513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus infection after kidney transplantation using cyclosporin A and low-dose prednisolone immunosuppression.
    Mayer G; Watschinger B; Pohanka E; Graf H; Popow T; Ulrich W; Kovarik J
    Nephrol Dial Transplant; 1988; 3(4):464-8. PubMed ID: 2845305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incidence of cytomegalo- and herpes simplex virus infections in renal allograft recipients treated with high dose recombinant leucocyte interferon: a controlled study.
    Weimar W; Kramer P; Bijnen AB; Jeekel J; Rothbarth PH; Masurel N
    Scand J Urol Nephrol Suppl; 1985; 92():37-9. PubMed ID: 3008315
    [No Abstract]   [Full Text] [Related]  

  • 5. Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation.
    Meyers JD; Flournoy N; Sanders JE; McGuffin RW; Newton BA; Fisher LD; Lum LG; Appelbaum FR; Doney K; Sullivan KM
    Ann Intern Med; 1987 Dec; 107(6):809-16. PubMed ID: 2825571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients.
    Kramer P; ten Kate FW; Bijnen AB; Jeekel J; Weimar W
    Lancet; 1984 May; 1(8384):989-90. PubMed ID: 6143968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients.
    Lewis RM; Johnson PC; Golden D; Van Buren CT; Kerman RH; Kahan BD
    Transplantation; 1988 Feb; 45(2):353-9. PubMed ID: 2830686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, placebo-controlled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients.
    Lui SF; Ali AA; Grundy JE; Fernando ON; Griffiths PD; Sweny P
    Nephrol Dial Transplant; 1992; 7(12):1230-7. PubMed ID: 1337164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B; Light S; Hardie IR; Lin A; Johnson JR
    Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections.
    Cheeseman SH; Rubin RH; Stewart JA; Tolkoff-Rubin NE; Cosimi AB; Cantell K; Gilbert J; Winkle S; Herrin JT; Black PH; Russell PS; Hirsch MS
    N Engl J Med; 1979 Jun; 300(24):1345-9. PubMed ID: 220536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts.
    Balfour HH; Chace BA; Stapleton JT; Simmons RL; Fryd DS
    N Engl J Med; 1989 May; 320(21):1381-7. PubMed ID: 2541335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients.
    Rostaing L; Izopet J; Baron E; Duffaut M; Puel J; Durand D
    Transplantation; 1995 May; 59(10):1426-31. PubMed ID: 7770930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of human interferon-beta on life-threatening viral pneumonitis in kidney transplant recipients.
    Takahashi K; Teraoka S; Yagisawa T; Fuchinoue S; Honda H; Toma H; Agishi T; Ota K
    Transplant Proc; 1987 Oct; 19(5):4089-95. PubMed ID: 2823438
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone.
    Moran M; Mozes MF; Maddux MS; Veremis S; Bartkus C; Ketel B; Pollak R; Wallemark C; Jonasson O
    N Engl J Med; 1990 Apr; 322(17):1183-8. PubMed ID: 2109195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
    Ponticelli C; Yussim A; Cambi V; Legendre C; Rizzo G; Salvadori M; Kahn D; Kashi H; Salmela K; Fricke L; Heemann U; Garcia-Martinez J; Lechler R; Prestele H; Girault D;
    Transplantation; 2001 Oct; 72(7):1261-7. PubMed ID: 11602853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
    Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary infections. The Minnesota randomized prospective trial of cyclosporine vs azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.
    Hesse UJ; Fryd DS; Chatterjee SN; Simmons RL; Sutherland DE; Najarian JS
    Arch Surg; 1986 Sep; 121(9):1056-60. PubMed ID: 3527111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral infections in kidney transplant patients immunosuppressed with cyclosporine.
    Takahashi K; Yagisawa T; Teraoka S; Toma H; Agishi T; Ota K; Kobayashi S
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2142-9. PubMed ID: 3029916
    [No Abstract]   [Full Text] [Related]  

  • 20. The Japanese Interferon Study Group (JISG) has established the efficacy of human interferon-beta for serious CMV pneumonitis in kidney recipients. Japanese Interferon Study Group.
    Takahashi K; Teraoka S; Ota K; Kosaki M; Okazaki H;
    Transpl Int; 1992; 5 Suppl 1():S133-7. PubMed ID: 14628737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.